Navigation Links
MiMedx Group Announces Record First Quarter Results
Date:5/2/2012

KENNESAW, Ga., May 2, 2012 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter  ended March 31, 2012.

  • Revenue Increases over 250%
  • Positive Adjusted EBITDA* Achieved for the First Time in Company History
  • Company Achieves Another Reimbursement Milestone for EpiFix®
  • Highlights of First Quarter 2012 ResultsThe Company recorded record revenue for the first quarter of 2012, with revenue of $3.7 million, a 255% or $2.7 million increase over first quarter of 2011 revenue of $1.0 million, and a 41% increase over fourth quarter of 2011 revenue of $2.6 million.  The Company's earnings before interest, taxes, depreciation, amortization and share-based compensation (Adjusted EBITDA*) for the quarter ended March 31, 2012, were a record high of $314,000, a $2.6 million improvement as compared to the Adjusted EBITDA loss of $2.3 million for the first quarter of 2011. The Company also reported record gross margins for the quarter.

    Management Commentary on First Quarter ResultsParker H. "Pete" Petit, Chairman and CEO, stated, "We have worked diligently to achieve positive EBITDA for the first quarter. This is a very important milestone for our shareholders, and we are very pleased that we have passed the threshold into positive EBITDA, which is a signal that we are approaching positive cash flow.  Our first quarter results were driven not only by increased revenue, but also by dramatically improved gross margins and reduced spending in research and development. Our reported gross margins for the first quarter were 74%, more than a twofold improvement over 2011 gross margins of 32%.  Sales in the wound care, spine and orthopedics/sports medicine markets were
    '/>"/>

    SOURCE MiMedx Group, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. MiMedx Group Announces Temporary Trading Symbol Designation
    2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
    3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
    4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
    5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
    6. MiMedx Announces Launch of AmnioFix™
    7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
    8. MiMedx Group Announces 2010 Results
    9. MiMedx Group Announces First Quarter 2011 Results
    10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
    11. MiMedx Group Completes $5,000,000 Private Placement
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
    (Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
    (Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
    (Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
    Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
    ... COTTAGE, N.Y., Jan. 28 XTL Biopharmaceuticals Ltd. (Nasdaq: ... its December 8, 2008 press release regarding the Company,s activities ... company to merge into or with XTL. The Company is ... it by both US and foreign-based companies who operate in ...
    ... as VP of Business Development , ... Olyphant, PA (PRWEB) January 28, ... company, announced today the hiring of Mr. Terry Ladd as Vice President ... 1994-2003 as Executive Director, Business Development and Marketing., , , , ,Mr. ...
    ... PALO ALTO, Calif., Jan. 28 In light of an ... (Nasdaq: CVTX ) confirmed that it had received ... an unsolicited proposal by Astellas to acquire CV Therapeutics at ... Astellas board approval and other conditions. After careful deliberation, ...
    Cached Biology Technology:XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives 2Calvert Labs Announces the Hiring of Terry Ladd 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3
    (Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
    (Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
    (Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
    Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
    ... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
    ... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
    ... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
    Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
    ... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: reusable ...
    ... LS Low Speed Shaker ,Product ... speed shaker is a high quality, general purpose ... ,Styled after the other models in the line, ... with easy-access control panel. Electronic controls are utilized ...
    ... CromoCenSC is a chromogenic medium for ... of Salmonella (except S. thyphi) and ... ,The detection takes a maximum of ... tests, no sterilization during preparation and ...
    ... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
    Biology Products: